Reply to Luppi et al

doi:10.1093/cid/ciaa324

Comment

. 2020 Dec 15;71(12):3266.

doi: 10.1093/cid/ciaa324.

Reply to Luppi et al

John R Wingard¹, Johan Maertens^{2

3}, Livio Pagano^{4

5}, Sharon C-A Chen⁶, Peter G Pappas⁷, J Peter Donnelly⁸

Affiliations

¹ Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
² Department of Hematology, University Hospitals Leuven, Leuven, Belgium.
³ Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
⁴ Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico A. Gemelli, IRCCS , Rome, Italy.
⁵ Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
⁶ Centre for Infectious Diseases and Microbiology, Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, University of Sydney, Sydney, Australia.
⁷ Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
⁸ Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

PMID: 32412052
PMCID: PMC7819513
DOI: 10.1093/cid/ciaa324

Comment

Reply to Luppi et al

John R Wingard et al. Clin Infect Dis. 2020.

. 2020 Dec 15;71(12):3266.

doi: 10.1093/cid/ciaa324.

Authors

John R Wingard¹, Johan Maertens^{2

3}, Livio Pagano^{4

5}, Sharon C-A Chen⁶, Peter G Pappas⁷, J Peter Donnelly⁸

Affiliations

¹ Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
² Department of Hematology, University Hospitals Leuven, Leuven, Belgium.
³ Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
⁴ Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico A. Gemelli, IRCCS , Rome, Italy.
⁵ Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
⁶ Centre for Infectious Diseases and Microbiology, Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, University of Sydney, Sydney, Australia.
⁷ Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
⁸ Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

PMID: 32412052
PMCID: PMC7819513
DOI: 10.1093/cid/ciaa324

No abstract available

PubMed Disclaimer

Comment on

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.
Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, Kontoyiannis DP, Kullberg BJ, Lagrou K, Lamoth F, Lehrnbecher T, Loeffler J, Lortholary O, Maertens J, Marchetti O, Marr KA, Masur H, Meis JF, Morrisey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, Roilides E, Ruhnke M, Prokop CS, Shoham S, Slavin MA, Stevens DA, Thompson GR, Vazquez JA, Viscoli C, Walsh TJ, Warris A, Wheat LJ, White PL, Zaoutis TE, Pappas PG. Donnelly JP, et al. Clin Infect Dis. 2020 Sep 12;71(6):1367-1376. doi: 10.1093/cid/ciz1008. Clin Infect Dis. 2020. PMID: 31802125 Free PMC article.
Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity.
Luppi M, Forghieri F, Potenza L. Luppi M, et al. Clin Infect Dis. 2020 Dec 15;71(12):3265-3266. doi: 10.1093/cid/ciaa323. Clin Infect Dis. 2020. PMID: 32412056 No abstract available.

Cited by

Mixed Aspergillosis and Mucormycosis Infections in Patients with COVID-19: Case Series and Literature Review.
Sasani E, Pakdel F, Khodavaisy S, Salehi M, Salami A, Sohrabi M, Aminishakiba P, Amirafzali I, Salami Khaneshan A. Sasani E, et al. Mycopathologia. 2024 Jan 17;189(1):10. doi: 10.1007/s11046-023-00808-z. Mycopathologia. 2024. PMID: 38231407 Review.

References

1. Luppi M, Forghieri F, Potenza L. Ibrutinib is a newly recognized host factor for the definition of probable invasive pulmonary mold disease, based on off-target effects, unrelated to its B cell immunesuppressant activity. Clin Infect Dis 2020; 71:3266–7. - PubMed
1. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium [manuscript published online ahead of print 5 December 2019]. Clin Infect Dis 2019. doi:10.1093/cid/ciz1008. - PMC - PubMed
1. Burger JA, Tedeschi A, Barr PM, et al. RESONATE-2 Investigators Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373:2425–37. - PMC - PubMed
1. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507–16. - PMC - PubMed
1. Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017; 129:2224–32. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Luppi M, Forghieri F, Potenza L. Ibrutinib is a newly recognized host factor for the definition of probable invasive pulmonary mold disease, based on off-target effects, unrelated to its B cell immunesuppressant activity. Clin Infect Dis 2020; 71:3266–7. - PubMed

[2] Luppi M, Forghieri F, Potenza L. Ibrutinib is a newly recognized host factor for the definition of probable invasive pulmonary mold disease, based on off-target effects, unrelated to its B cell immunesuppressant activity. Clin Infect Dis 2020; 71:3266–7. - PubMed

[3] Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium [manuscript published online ahead of print 5 December 2019]. Clin Infect Dis 2019. doi:10.1093/cid/ciz1008. - PMC - PubMed

[4] Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium [manuscript published online ahead of print 5 December 2019]. Clin Infect Dis 2019. doi:10.1093/cid/ciz1008. - PMC - PubMed

[5] Burger JA, Tedeschi A, Barr PM, et al. RESONATE-2 Investigators Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373:2425–37. - PMC - PubMed

[6] Burger JA, Tedeschi A, Barr PM, et al. RESONATE-2 Investigators Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373:2425–37. - PMC - PubMed

[7] Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507–16. - PMC - PubMed

[8] Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507–16. - PMC - PubMed

[9] Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017; 129:2224–32. - PMC - PubMed

[10] Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017; 129:2224–32. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to Luppi et al

Affiliations

Reply to Luppi et al

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical